| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2021 | DVAX Dynavax Technologies Corp | Burgess Justin60 | Principal Accounting Officer | Sell | 4,123 | $8.86 | $36,542.34 | -14.2% | - | - | |
| Mar 1, 2021 | ZTS Zoetis Inc. | Kelly Robert Edward | Executive Vice President | Sell | 2,055 | $156.11 | $320,806.05 | -18.1% | +10.6% | +22.8% | |
| Mar 1, 2021 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 37,279 | $99.30 | $3,701,646.98 | -32.8% | - | - | |
| Mar 1, 2021 | LNTH Lantheus Holdings, Inc. | Bolla John J. | Chief Operations Officer | Sell | 1,187 | $19.08 | $22,650.33 | -2.0% | - | - | |
| Mar 1, 2021 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | President And CEO | Sell | 64,768 | $22.67 | $1,468,424.74 | -10.3% | - | - | |
| Mar 1, 2021 | LNTH Lantheus Holdings, Inc. | Duffy Michael P | SVP And General Counsel | Sell | 1,473 | $19.08 | $28,107.79 | -1.4% | - | - | |
| Mar 1, 2021 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 1,465 | $19.08 | $27,955.13 | -1.8% | - | - | |
| Mar 1, 2021 | PCRX Pacira Biosciences, Inc. | Longenecker John P Phd | Director | Sell | 5,000 | $72.26 | $361,300.00 | -22.0% | - | - | |
| Mar 1, 2021 | CRON Cronos Group Inc. | Jacobson Jeffrey David | See Remarks | Sell | 4,500 | $13.60 | $61,200.90 | -100% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 7,486 | $10.83 | $81,079.37 | -9.8% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 73,127 | $10.91 | $798,022.67 | -37.3% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 10,912 | $10.83 | $118,185.69 | -8.7% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | Sell | 75,587 | $10.87 | $821,924.63 | -55.6% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 9,795 | $10.85 | $106,284.57 | -16.6% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 20,598 | $10.85 | $223,506.84 | -65.7% | - | - | |
| Mar 1, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 18,430 | $10.83 | $199,611.64 | -86.1% | - | - | |
| Mar 1, 2021 | AKBA Akebia Therapeutics, Inc. | Faulkingham Dell70 | CCO | Sell | 6,749 | $3.40 | $22,920.28 | -5.0% | +1.3% | -36.1% | |
| Mar 1, 2021 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 7,558 | $3.40 | $25,667.72 | -4.5% | +1.3% | -36.1% | |
| Mar 1, 2021 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Operating Officer | Sell | 14,547 | $3.40 | $49,403.07 | -2.7% | +1.3% | -36.1% | |
| Mar 1, 2021 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, Chief Legal Officer | Sell | 14,285 | $3.40 | $48,513.29 | -2.6% | +1.3% | -36.1% | |
| Mar 1, 2021 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 49,990 | $3.40 | $169,771.04 | -2.2% | +1.3% | -36.1% | |
| Mar 1, 2021 | COLL Collegium Pharmaceutical, Inc | Fleming Alison B | Chief Technical Officer | Sell | 18,235 | $22.60 | $412,168.96 | -1.7% | - | - | |
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | Owens Edward P | Director | Buy | 3,000 | $8.90 | $26,700.00 | +1.4% | - | - | |
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | SVP, CFO &Treasurer | Sell | 18,406 | $9.11 | $167,678.66 | -1.3% | - | - | |
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | President | Sell | 14,685 | $9.11 | $133,780.35 | -1.0% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.